SBT-300

N/A

Report date: 2022/06/17 16:22:45

Base Information

Drug NameSBT-300

Drug Alias NameSBT-300

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitorsSignal transducer and activator of transcription 3 inhibitors

TargetsGTPase KRasSignal transducer and activator of transcription 3

Therapy Area/IndicationsKeratosis, ActinicSkin Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSingh Biotechnology Llc

China Registration ClassN/A

Develop Information

Active CompaniesSingh Biotechnology Llc

Inactive CompaniesN/A

Active IndicationsKeratosis, ActinicSkin Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A